

NOTICE OF MATERIAL CHANGE TO CONTRACT



September 1, 2021

Re: Anthem prior authorization updates for specialty pharmacy are available

Dear Provider:

Anthem Blue Cross and Blue Shield and our subsidiary company, HMO Colorado (Anthem), is writing to inform you of the following authorization updates for specialty pharmacy.

Prior authorization updates

Effective for dates of service on and after December 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.

Clinical Criteria	HCPCS or CPT Code(s)	Drug
*ING-CC-0201	J9999	Rybrevent

*Oncology use is managed by AIM Specialty Health® (AIM).

Quantity limit updates

Effective for dates of service on and after December 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process.

Clinical Criteria	HCPCS or CPT Code(s)	Drug
ING-CC-0050	J3490, J3590	Skyrizi (risankizumab-rzaa)
ING-CC-0075	Q5123	Riabni (rituximab-arrr)

Please note, inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.


To access the Clinical Criteria information, go to:

<https://www.anthem.com/ca/ms/pharmacyinformation/clinicalcriteria.html>

Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by the medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by AIM.

We value and appreciate you as our partner in providing quality care and appreciate your continued participation in our network.

Sincerely,

A handwritten signature in black ink, appearing to read "Jonathan Sollender". The signature is fluid and cursive, with a long, sweeping underline that extends to the left.

Jonathan Sollender, MD, MBA, FACS
Regional Vice President and Senior Clinical Officer
Commercial & Specialty Business Division